Andrew W Silagy1, Jessica Flynn2, Roy Mano3, Kyle A Blum3, Julian Marcon4, Renzo G DiNatale3, Alejandro Sanchez3, Maria I Carlo5, Robert J Motzer5, Jonathan A Coleman3, Paul Russo3, Irina Ostrovnaya2, Yingbei B Chen6, Ari A Hakimi7. 1. Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia. 2. Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, University Hospital of Munich, Munich, Germany. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 7. Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: hakimia@mskcc.org.
Abstract
OBJECTIVES: To report the overall survival (OS) outcomes of patients with nonclear cell renal cell carcinoma (nccRCC) treated at our institution with a cytoreductive nephrectomy (CN) and better understand the clinical and pathological characteristics of the patients that respond best. MATERIAL AND METHODS: We queried our prospectively maintained database for patients who underwent CN for nccRCC between 1989 and 2018. Histology was reviewed by an expert genitourinary pathologist, and nccRCC tumors were subdivided into papillary, unclassified, chromophobe, and other histology. Baseline clinicopathology, treatments, and survival outcomes were recorded. Preoperative hematological parameters including the neutrophil-to-lymphocyte ratio (NLR) were analyzed. Significant univariate predictors of OS were tested in a multivariate model. RESULTS: There were 100 nccRCC patients treated with CN. Median age was 61 years (IQR: 48-69) and 65% were male. There were 79 patient deaths with a median OS of 13.7 months (10.8-27.2). Estimated 2- and 5-year survival was 40.1% and 12.2%, respectively. Median follow-up of survivors was 13 months (IQR: 3-30). On multivariate analysis, increasing NLR (hazard ratio [HR] 1.27; 95% confidence interval [CI] 1.14-1.40, P < 0.001) and sarcomatoid features (HR 2.18; 95% CI 1.19-3.97, P = 0.014) conferred worse OS and the presence of papillary features were a favorable prognostic feature (HR 0.37; 95% CI 0.21-0.65, P < 0.001). CONCLUSIONS: OS outcomes in patients with nccRCC who underwent a CN are consistently modest throughout the study period. Patients with papillary features and a lower preoperative NLR may be better candidates for a CN.
OBJECTIVES: To report the overall survival (OS) outcomes of patients with nonclear cell renal cell carcinoma (nccRCC) treated at our institution with a cytoreductive nephrectomy (CN) and better understand the clinical and pathological characteristics of the patients that respond best. MATERIAL AND METHODS: We queried our prospectively maintained database for patients who underwent CN for nccRCC between 1989 and 2018. Histology was reviewed by an expert genitourinary pathologist, and nccRCC tumors were subdivided into papillary, unclassified, chromophobe, and other histology. Baseline clinicopathology, treatments, and survival outcomes were recorded. Preoperative hematological parameters including the neutrophil-to-lymphocyte ratio (NLR) were analyzed. Significant univariate predictors of OS were tested in a multivariate model. RESULTS: There were 100 nccRCC patients treated with CN. Median age was 61 years (IQR: 48-69) and 65% were male. There were 79 patientdeaths with a median OS of 13.7 months (10.8-27.2). Estimated 2- and 5-year survival was 40.1% and 12.2%, respectively. Median follow-up of survivors was 13 months (IQR: 3-30). On multivariate analysis, increasing NLR (hazard ratio [HR] 1.27; 95% confidence interval [CI] 1.14-1.40, P < 0.001) and sarcomatoid features (HR 2.18; 95% CI 1.19-3.97, P = 0.014) conferred worse OS and the presence of papillary features were a favorable prognostic feature (HR 0.37; 95% CI 0.21-0.65, P < 0.001). CONCLUSIONS:OS outcomes in patients with nccRCC who underwent a CN are consistently modest throughout the study period. Patients with papillary features and a lower preoperative NLR may be better candidates for a CN.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: M H Voss; D A Bastos; C A Karlo; A Ajeti; A A Hakimi; D R Feldman; J J Hsieh; A M Molina; S Patil; R J Motzer Journal: Ann Oncol Date: 2014-01-23 Impact factor: 32.976
Authors: Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri Journal: Eur Urol Date: 2014-06-13 Impact factor: 20.096
Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Wassim Kassouf; Ricardo Sanchez-Ortiz; Pheroze Tamboli; Nizar Tannir; Eric Jonasch; Madhur M Merchant; Surena Matin; David A Swanson; Christopher G Wood Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: D Lorente; J Mateo; A J Templeton; Z Zafeiriou; D Bianchini; R Ferraldeschi; A Bahl; L Shen; Z Su; O Sartor; J S de Bono Journal: Ann Oncol Date: 2014-12-23 Impact factor: 32.976
Authors: Andrew W Silagy; Ritesh R Kotecha; Stanley Weng; Arturo Holmes; Nirmish Singla; Roy Mano; Kyrollis Attalla; Kate L Weiss; Renzo G DiNatale; Sujata Patil; Jonathan A Coleman; Robert J Motzer; Paul Russo; Martin H Voss; A Ari Hakimi Journal: Cancer Date: 2021-07-19 Impact factor: 6.860